Incannex Granted Patent for Obstructive Sleep Apnea Treatment
Incannex announced that the United States Patent and Trademark Office, or USPTO, has granted a patent titled "Compositions and Methods of Treatment for Obstructive Sleep Apnea." The granted patent includes claims directed to the proprietary IHL-42X composition and its associated therapeutic methods for the treatment of Obstructive Sleep Apnea, or OSA. The patent is expected to have a baseline expiry date of July 9, 2040 and the company is exploring its eligibility for patent term extension following potential FDA approval.
